-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33

Benzinga·05/15/2026 17:33:21
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $34 to $33.